Importantly, depletion of CD8+ T cells, but not CD4+ T cells, in ABX-treated B16-F0 tumor-bearing mice dampened the antitumor effect of butyrate combined with anti-PD-1 (Figure 4b–e). This evidence concerns the gene CD4 and neoplasm.